Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Allovir Inc (ALVR)

Allovir Inc (ALVR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 283,914
  • Shares Outstanding, K 65,418
  • Annual Sales, $ 0 K
  • Annual Income, $ -171,960 K
  • 60-Month Beta 1.86
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.45
Trade ALVR with:

Options Overview Details

View History
  • Implied Volatility 122.02% ( +16.25%)
  • Historical Volatility 137.54%
  • IV Percentile 85%
  • IV Rank 20.97%
  • IV High 303.92% on 03/31/22
  • IV Low 73.76% on 09/14/21
  • Put/Call Vol Ratio 3.00
  • Today's Volume 24
  • Volume Avg (30-Day) 1,281
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 10,557
  • Open Int (30-Day) 9,843

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.70
  • Number of Estimates 4
  • High Estimate -0.62
  • Low Estimate -0.74
  • Prior Year -0.60
  • Growth Rate Est. (year over year) -16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.21 +42.06%
on 05/12/22
8.51 -46.42%
on 04/20/22
-1.10 (-19.43%)
since 04/14/22
3-Month
3.21 +42.06%
on 05/12/22
9.28 -50.89%
on 03/02/22
-3.50 (-43.42%)
since 02/17/22
52-Week
3.21 +42.06%
on 05/12/22
26.41 -82.73%
on 10/01/21
-19.18 (-80.79%)
since 05/17/21

Most Recent Stories

More News
AlloVir Reports First Quarter 2022 Financial Results

AlloVir, Inc. (Nasdaq: ALVR), a multiple Phase 3 clinical trial stage allogeneic T cell immunotherapy company, today reported financial results for the first quarter ended March 31, 2022. The company also...

ALVR : 4.55 (+4.84%)
AlloVir (ALVR) Up on Third RMAT Status From FDA for Posoleucel

The FDA bestows a third Regenerative Medicine Advanced Therapy designation to AlloVir's (ALVR) lead candidate, posoleucel, for preventing life-threatening infections from six viruses. Shares rise.

NERV : 0.4001 (+2.59%)
CRBP : 0.2912 (-2.22%)
ALVR : 4.55 (+4.84%)
GMTX : 1.4000 (+5.26%)
Why Is AlloVir (ALVR) Stock Up 30% Today?

ALVR got an update from the FDA today

NDAQ : 148.33 (+1.51%)
TSLA : 750.23 (+3.57%)
ALVR : 4.55 (+4.84%)
FUBO : 3.32 (+1.84%)
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients

AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy...

ALVR : 4.55 (+4.84%)
AlloVir Becomes Oversold (ALVR)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

ALVR : 4.55 (+4.84%)
AlloVir Appoints Shawn Tomasello to Its Board of Directors

AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced the appointment of Shawn Tomasello to its Board of Directors. Ms. Tomasello brings more than 35 years...

ALVR : 4.55 (+4.84%)
AlloVir (ALVR) Begins Study to Prevent Six Viral Infections

AlloVir (ALVR) starts a phase III study on its lead candidate, posoleucel, for the prevention of life-threatening viral infections from six common viruses. Shares up.

NERV : 0.4001 (+2.59%)
CRBP : 0.2912 (-2.22%)
ALVR : 4.55 (+4.84%)
GMTX : 1.4000 (+5.26%)
AlloVir Initiates Global Phase 3 Registrational Study of Posoleucel for Prevention of Life-Threatening Viral Infections from Six Common Viruses in High-Risk, Allogeneic Hematopoietic Cell Transplant Patients

AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced the initiation of a Phase 3 registrational study of posoleucel, an allogeneic, off-the-shelf, multi-virus-specific...

ALVR : 4.55 (+4.84%)
AlloVir to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the 11th...

ALVR : 4.55 (+4.84%)
AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook

AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today reported full-year 2021 financial results for the period ended December 31, 2021. The company also provided...

ALVR : 4.55 (+4.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AlloVir, Inc. is a late clinical-stage cell therapy company which focus on restoring natural immunity against life-threatening viral diseases. AlloVir, Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 4.82
2nd Resistance Point 4.63
1st Resistance Point 4.48
Last Price 4.55
1st Support Level 4.14
2nd Support Level 3.95
3rd Support Level 3.80

See More

52-Week High 26.41
Fibonacci 61.8% 17.55
Fibonacci 50% 14.81
Fibonacci 38.2% 12.07
Last Price 4.55
52-Week Low 3.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar